MecaserminRecombinant growth-factor medicine
Mecasermin is recombinant human IGF-1. Its role concerns specific growth disorders, not a general attempt to increase muscle, height or recovery in otherwise healthy people.
What is Mecasermin?
Mecasermin is recombinant human insulin-like growth factor 1 (IGF-1), used for a defined form of severe primary IGF-1 deficiency affecting childhood growth. It is not a general treatment for short stature. 1 2
How it works
IGF-1 acts downstream of growth hormone in growth signalling. Replacing IGF-1 therefore addresses a different hormonal problem from replacing growth hormone itself. 2
Effects studied
What does the evidence show?
Specific paediatric growth-disorder studies; archived label retained
A step downstream of growth hormone
Growth hormone stimulates several processes, including production of insulin-like growth factor 1. Mecasermin supplies IGF-1 directly. This makes it biologically distinct from somatropin, which supplies growth hormone, and from medicines that stimulate the pituitary to release more of it.
Why the diagnosis changes the treatment
In severe primary IGF-1 deficiency, the problem is not simply an insufficient growth-hormone signal. Direct IGF-1 replacement can therefore address a different point in the pathway. Ordinary short stature, nutritional problems and other causes of impaired growth should not be treated as interchangeable diagnoses.
What clinical benefit looks like
Research in children may examine how quickly they grow and their longer-term height. Age, remaining growth potential and the underlying disorder help determine what those measurements mean. They do not establish a benefit for adult athletic performance or justify raising an already adequate growth-factor level.
A growth signal has other effects
Hypoglycaemia is an important concern. Tonsillar growth, intracranial hypertension and malignancy-related precautions also need to be considered, so specialist monitoring goes beyond measuring height. Mecasermin replaces a specific signal in a defined disorder. It is neither a general restorative treatment nor another name for growth hormone.
Safety & status
Hypoglycaemia is a major concern. Tonsillar enlargement, intracranial hypertension and malignancy-related restrictions also feature in the product’s safety context. 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is mecasermin the same as growth hormone?
No. It supplies IGF-1, a different signal downstream of growth hormone. 2
Is a faster growth rate the same as a proven adult-height gain?
No. Growth over a treatment interval and final adult height must be assessed separately. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Mecasermin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Mecasermin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.